We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
October saw the highest number of drug approvals of any month in 2006, which could become a record year for drug approvals, according to research by Friedman, Billings, Ramsey (FBR). Read More
More than one out of seven members of institutional review boards (IRBs) have approved at least one protocol in the previous year under circumstances that “could be considered conflicts of interest,” according to the results of a survey published in the New England Journal of Medicine. Read More
VaxGen said HHS’ Office of Public Health Emergency Preparedness has imposed Dec. 18 as the new deadline for the company to begin its next Phase II clinical trial for its next-generation anthrax vaccine, although the FDA put a clinical hold on the trial. Read More
October saw the highest number of drug approvals of any month in 2006, which could become a record year for drug approvals, according to research by Friedman, Billings, Ramsey (FBR). Read More
Barr Pharmaceuticals’ newly acquired subsidiary Pliva has won final FDA approval to market Pravastatin (pravastatin sodium), a generic version of Bristol-Myers Squibb’s (BMS) cholesterol-lowering drug Pravachol. Read More
Teva Pharmaceutical has won FDA approval to market generic versions of GlaxoSmithKline’s (GSK) Zofran, a drug used to treat vomiting and nausea caused by cancer chemotherapy. Read More
Herceptin can now be used with chemotherapy to treat HER2-positive breast cancer patients after surgery to reduce relapses, the FDA announced. Read More
The European Commission (EC) approved the first diabetes drug in a new class to control glucose levels and possibly reduce weight, Eli Lilly announced. Read More
The FDA has given specialty drugmaker Fougera approval to market its acne treatment sulfacetamide sodium topical suspension 10 percent strength, a generic version of Dermik’s Klaron. Read More